Beskrone v. Berlin

United States Bankruptcy Court, D. Delaware·Decided July 14, 2025·No. 23-50336·Unknown

Opinion

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Chapter 7 ROSETTA GENOMICS, INC. Case No. 18-11316 (LSS) Debtor. Jointly Administered

DON A. BESKRONE, not individually, but solely as Chapter 7 trustee for ROSETTA GENOMICS, INC.,, Plaintiff, Adv. Pro. No. 23-50336 (LSS) v. Kenneth A. Berlin, Ron Kalfus, and Brian Markison, Defendants.

MEMORANDUM Before the Court is the Motion' filed by Kenneth Berlin, Ron Kalfus and Brian Markison (each a “Defendant” and coilectively, “Defendants”) to dismiss the Complaint? filed by Don Beskrone (“Plaintiff”) in his capacity as chapter 7 trustee for Rosetta Genomics, Inc. (“Debtor”). Defendants argue that the Complaint should be dismissed pursuant to Federal Rules of Civil Procedure (“Civil Rules”) 12(b)(2), 12(b)(6), the doctrine of forum non conveniens and Delaware’s statute of limitations.? Defendants also request that this Court withdraw the

' Defs.’ Mot. to Dismiss Compl., Dkt. No. 23 (“Motion”). ? Compl. for Damages, Dkt. No. 1 (“Complaint”). Motion; Mem. Law Supporting Defs.’ Mot. Dismiss Compl. 8, Dkt. No. 24 (“Opening Br.”).

District Court’s reference to this Court. Finally, Defendants seck to dismiss the Complaint for failure to state a claim. For the reasons discussed below, with a single exception, the Motion is denied. FACTUAL BACKGROUND" The Debtor was a Delaware corporation with its principal place of business in Pennsylvania. Rosetta Genomics, Ltd. (“Parent”) was an Israeli company that formed Debtor as a wholly owned subsidiary to commercialize and expand its business in the United States. Defendants in this action are former directors and officers of Debtor and Parent. Berlin served as the CEO of Parent and as the sole director of Debtor. Kalfus served as the CFO of both Parent and Debtor. Markison served as the Chairman of Parent’s board of directors. Each Defendant is a citizen of New Jersey. Parent “develop[ed] and commercialize[d] new diagnostic tests based on various genomics markers, including DNA, mircoRNA and protein biomarkers and using various technologies, including qPCR, microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridizaton (FISH).”*> Debtor commercialized Parent’s products and performed tests in its laboratories to expand Parent’s business in the United States. Debtor’s most significant assets were its subsidiaries, Minuet Diagnostics, Inc. and CynoGen, Inc., as well as the diagnostic test RosettaGX Reveal (“Reveal”). Reveal accounted for 75%-85% of Debtor’s revenue.

4 As required. when considering a motion to dismiss, the facts recited herein are taken from the Complaint. Pension Benefit Guar. Corp. v. White Consol. Indus., Inc., 998 F.2d 1192, 1196 (3d Cir. 1993). > Complaint ¢ 43.

Parent also owned another diagnostic test, RosettaGX Cancer Origin Test (“Cancer Origin”). In 2012, Medicare established a retmbursement rate for Cancer Origin and published a formalized coverage decision through a Local Coverage Determination (“LCD”), This LCD meant that Debtor and/or Parent received approved, automatic payments for claims submitted to Medicare and private insurers for Cancer Origin. There was no LCD for the Reveal! test. If the Reveal test was correctly coded, it was rarely reimbursed. But, it was often billed under the coding for Cancer Origin such that reimbursement was “automatic.”® Prior to 2017, miscoded Reveal tests were reimbursed by Medicare in 90% of cases. By February 2018, after the miscoding was discovered, Medicare reimbursement rates plummeted to less than 5%. Defendants knew of the false coding no later than mid-June 2017. Internal documents reveal that Berlin sent a message to Debtor’s general counsel stating that the false coding had been present “from Day One.”” A, PUBLIC FILINGS AND THE SECURITIES PURCHASE AGREEMENTS. On September 26, 2016, Parent filed its Form 6-K, which included its June 30, 2016 unaudited financial statements. The form 6-K was signed by Kalfus. Parent reported revenues on Reveal tests, but did not disclose that Reveal tests were being billed as Cancer Origin, Parent entered into a Securities Purchase Agreement in November 2016 (the “2016 SPA”) with Sabby Healthcare Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (collectively, “Sabby”). Pursuant to the 2016 SPA, Sabby tendered $3,160,000 to Parent and received 1,095,000 ordinary shares and other warrants in exchange. This

§ Complaint q 45. ? Complaint 4 45.

agreement was executed by Berlin, who made numerous statements regarding Parent’s revenues, assets and liabilities. Berlin did not disclose the miscoding. The 2016 SPA, a direct placement subject to Parent’s then-current Registration Statement, incorporated the 2016 Form 6-K, the Prospectus and the Prospectus Supplement. The 6-K and the 2016 SPA contain warranties that the incorporated financial statements complied with Generally Accepted Accounting Principles (GAAP) and “fairly present in all material respects the financial position of [Parent] and its consolidated subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited financial statements, to normal, immaterial, year-end audit adjustments.”® These documents did not disclose that Reveal’s high reimbursement rate and revenue were due to the false coding. Parent acknowledged that Sabby was relying on its representations in entering into the 2016 SPA. Debtor provided an absolute guaranty of the 2016 SPA. It also adopted Parent’s representations and warranties as they related to Debtor. Debtor did not disclose that Reveal revenues and reimbursement rates were based on false coding or that if discovered, this could lead to a material decline in reimbursement rates. On March 30, 2017, Parent filed its 20-F, which included consolidated financial statements; this filing was certified by each of the Defendants. In June 2017, Defendants learned that the false coding of Reveal was under scrutiny by Medicare. In response, Defendants “purported” to launch an internal investigation and “purported” to “fix” the miscoding.’ Notwithstanding the internal acknowledgement of the

® Complaint 4 52. Complaint § 63.

4,

Free access — add to your briefcase to read the full text and ask questions with AI

Beskrone v. Berlin, (Del. 2025).

Beskrone v. Berlin (Beskrone v. Berlin) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Milliken v. Meyer
311 U.S. 457 (Supreme Court, 1941)
International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
Gulf Oil Corp. v. Gilbert
330 U.S. 501 (Supreme Court, 1947)
Celotex Corp. v. Edwards
514 U.S. 300 (Supreme Court, 1995)
Windt v. Qwest Communications International, Inc.
529 F.3d 183 (Third Circuit, 2008)
Geyer v. Ingersoll Publications Co.
621 A.2d 784 (Court of Chancery of Delaware, 1992)
Russell v. Olmedo
275 A.2d 249 (Supreme Court of Delaware, 1971)
Chrysler First Business Credit Corp. v. 1500 Locust Ltd. Partnership
669 A.2d 104 (Supreme Court of Delaware, 1995)
General Foods Corporation v. Cryo-Maid, Inc.
198 A.2d 681 (Supreme Court of Delaware, 1964)
Reid v. Spazio
970 A.2d 176 (Supreme Court of Delaware, 2009)
Stapleton v. King
33 Iowa 28 (Supreme Court of Iowa, 1871)
Marnavi S.p.A. v. Keehan
900 F. Supp. 2d 377 (D. Delaware, 2012)